Evaluating Clinical Practice Guidelines for Multiple Myeloma in Latin America

Photo | Roshni Saleem Chagan
Roshni Saleem Chagan
Consultant, Policy & Insights, Economist Enterprise

19 May 2025

A doctor is filling holographic patient check list

Multiple myeloma (MM), a haematological malignancy characterised by the abnormal expansion of plasma cells in the bone marrow, accounts for 1% of all cancers and 10% of haematologic malignancies globally. CPGs play a significant role in shaping treatment patterns and patient outcomes, providing specific recommendations on treatments, disease management, accessibility, and more. Having a clinical practice guideline in place is not enough; the ability to successfully apply what is written in the guidelines is equally important. The application of guidelines also varies within the region, highlighting critical gaps that must be filled in order to create an enabling environment. Some countries within the region are making efforts to work towards an enabling environment which ensures the application of clinical guidelines in practice, but there is still work to be done.

Clinical practice guidelines vary in the region

The existence and nature of clinical practice guidelines vary across the region. While some countries have active and up-to-date guidelines, others have outdated guidelines. What is written in the guidelines in terms of best practices, treatment recommendations and specific drugs used vary across countries. Some countries in the region do not have their own guidelines, relying instead on international guidelines.

The public-private divide in implementing guidelines and accessing treatment

Disparities in the implementation of CPGs and treatment are most present between public and private institutions. Patients treated in the public sector face more difficulty than patients seeking care in private systems leading to fragmentation and gaps in care, as a result of resource access. Private institutions generally have greater access to resources relative to public institutions, creating disparities in the quality of care between public and private institutions.

LATAM’s regulatory and cost environment related to MM care and management are significant barriers to alignment on novel treatments in the public system. The approval process for reimbursements of novel agents results in significant wait times for patients reliant on public health services, which ultimately exacerbates disparities in treatment access between patients treated in public versus private settings. Though costs can be barriers, viewing healthcare costs as investments in patient access is integral for improving health outcomes.

There is room to improve the care landscape

The current bottlenecks can be alleviated by integrating CPGs across healthcare settings, allowing for such guidelines to be frequently updated with the best existing data, and thereby ensuring that guidelines are considered in decision-making when it comes to regulatory affairs, access, and reimbursement.

Concerted efforts to leverage a multidisciplinary approach in drafting clinical practice guidelines can ensure moving towards more equitable management of MM. The current gaps in availability of guidelines, differences in what is written in them, and lack of real-time data are areas to invest time and resources for improvements. Homologating clinical practice guidelines within the region can ensure the development of standardised care for MM that relies on the most up-to-date knowledge of the disease, while also working to ensure that gaps between public and private care are as limited as possible.